Nonrenal drug clearance in CKD: Searching for the path less traveled.

Patients with chronic kidney disease (CKD) represent a significant and growing segment of the US population. A mounting body of experimental and clinical evidence indicates that nonrenal drug clearance is altered in patients with CKD. Specific nonrenal clearance (CL(NR)) pathways that are affected have been identified in experimental models, and include cytochrome P450 enzymes, P-glycoprotein, and organic anion-transporting polypeptides. Altered CL(NR) of several drugs has been described in clinical pharmacokinetics studies, but to date the specific CL(NR) pathways that are affected in CKD patients and result in clinically significant changes in drug exposure have not been definitively established, and the mechanism has not been elucidated. Accumulated uremic toxins may downregulate or directly inhibit drug metabolism and transport pathways, and may do so in a reversible manner. Future Food and Drug Administration recommendations pertaining to the conduct of pharmacokinetic studies in CKD will undoubtedly facilitate the search for the CL(NR) path less traveled, clarify the mechanisms involved, improve our understanding of the clinical significance of altered CL(NR) of individual drugs, and lead to more comprehensive drug dosing recommendations for patients with CKD. This review summarizes our current understanding of this field, focusing on recent developments in the search for the CL(NR) "path less traveled" in CKD.

[1]  E. Kharasch,et al.  Use of Enantiomeric Bupropion and Hydroxybupropion to Assess CYP2B6 Activity in Glomerular Kidney Diseases , 2010, Journal of clinical pharmacology.

[2]  L. Benet,et al.  Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End‐Stage Renal Disease , 2010, Clinical pharmacology and therapeutics.

[3]  AW Dreisbach.  The Influence of Chronic Renal Failure on Drug Metabolism and Transport , 2009, Clinical pharmacology and therapeutics.

[4]  L. Zhang,et al.  When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective , 2009, Clinical pharmacology and therapeutics.

[5]  D. Weiner,et al.  Public Health Consequences of Chronic Kidney Disease , 2009, Clinical pharmacology and therapeutics.

[6]  T. Nolin,et al.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam. , 2009, Journal of the American Society of Nephrology : JASN.

[7]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[8]  N. Limdi,et al.  Kidney function influences warfarin responsiveness and hemorrhagic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[9]  L. Zhang,et al.  Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications , 2009, Clinical pharmacology and therapeutics.

[10]  R. Franke,et al.  Inhibition of imatinib transport by uremic toxins during renal failure. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Guillemette,et al.  Downregulation of hepatic acetylation of drugs in chronic renal failure. , 2008, Journal of the American Society of Nephrology : JASN.

[12]  T. Nolin,et al.  Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport , 2008, Clinical pharmacology and therapeutics.

[13]  R. Vanholder,et al.  What is new in uremic toxicity? , 2008, Pediatric Nephrology.

[14]  Pingfu Fu,et al.  Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Micheline Piquette-Miller,et al.  Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer , 2008, Drug Metabolism and Disposition.

[16]  T. Murakami,et al.  Intestinal efflux transporters and drug absorption. , 2008, Expert opinion on drug metabolism & toxicology.

[17]  O. Pelkonen,et al.  Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. , 2007, British journal of clinical pharmacology.

[18]  L. Benet,et al.  Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results , 2007, Clinical pharmacology and therapeutics.

[19]  F. Leblond,et al.  Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[20]  R. Orlando,et al.  Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis , 2006, Clinical pharmacology and therapeutics.

[21]  T. Nolin,et al.  Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. , 2006, Journal of the American Society of Nephrology : JASN.

[22]  J. Ritter,et al.  EFFECT OF CHRONIC RENAL INSUFFICIENCY ON HEPATIC AND RENAL UDP-GLUCURONYLTRANSFERASES IN RATS , 2006, Drug Metabolism and Disposition.

[23]  R. Kim,et al.  Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.

[24]  F. Leblond,et al.  Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450 , 2005, British journal of pharmacology.

[25]  Hong Sun,et al.  EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN , 2004, Drug Metabolism and Disposition.

[26]  S. Swan,et al.  The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. , 2004, Kidney international.

[27]  J. Barrett,et al.  Pharmacokinetics and Safety of the Ketolide Telithromycin in Patients with Renal Impairment , 2004, Journal of clinical pharmacology.

[28]  T. Nolin,et al.  Hepatic drug metabolism and transport in patients with kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  A. Rettie,et al.  Cytochrome P4502C9 activity in end‐stage renal disease , 2003, Clinical pharmacology and therapeutics.

[30]  Raymond Vanholder,et al.  Review on uremic toxins: classification, concentration, and interindividual variability. , 2003, Kidney international.

[31]  F. Leblond,et al.  Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators , 2002, British journal of pharmacology.

[32]  F. Leblond,et al.  Downregulation of intestinal cytochrome p450 in chronic renal failure. , 2002, Journal of the American Society of Nephrology : JASN.

[33]  K. Wilner,et al.  The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. , 2002, British journal of clinical pharmacology.

[34]  I. Yano,et al.  Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction , 2002, The Journal of pharmacy and pharmacology.

[35]  Karthik Venkatakrishnan,et al.  Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.

[36]  F. Leblond,et al.  Downregulation of hepatic cytochrome P450 in chronic renal failure. , 2001, Journal of the American Society of Nephrology : JASN.

[37]  S. Wrighton,et al.  The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*† , 2001, Drug metabolism reviews.

[38]  U. Hofmann,et al.  Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan , 1996, Clinical pharmacology and therapeutics.

[39]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[40]  I. Jang,et al.  Decreased acetylation of isoniazid in chronic renal failure , 1993, Clinical pharmacology and therapeutics.

[41]  L. Corcos,et al.  Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. , 1993, Molecular pharmacology.

[42]  S. Joel,et al.  The pharmacokinetics of morphine and morphine glucuronides in kidney failure , 1993, Clinical pharmacology and therapeutics.

[43]  G. R. Murray,et al.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. , 1991, British journal of clinical pharmacology.

[44]  J. Fillastre,et al.  Zidovudine disposition in patients with severe renal impairment: Influence of hemodialysis , 1989, Clinical pharmacology and therapeutics.

[45]  D. Shen,et al.  Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. , 1985, The Journal of pharmacology and experimental therapeutics.

[46]  T. D. Bell,et al.  ALTERED THEOPHYLLINE PHARMACOKINETICS DURING ACUTE RESPIRATORY VIRAL ILLNESS , 1978, The Lancet.

[47]  L. Nelson,et al.  Kinetics of procainamide and N-acetylprocainamide in renal failure. , 1977, Kidney international.

[48]  Sack Rb.  Letter: Serotyping of E. coli. , 1976, Lancet.

[49]  R. Sega,et al.  Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment , 1976, Clinical pharmacokinetics.